Novavax Inc

NVAX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
NVAX Income Statement
NVAX Balance Sheet
NVAX Cash Flow
Congress Trading

Recent trades of NVAX by members of U.S. Congress

Politician Type Traded
Pat Roberts Senate / R Sale (Full) $1,001 - $15,000 Oct. 13, 2020
Pat Roberts Senate / R Purchase $1,001 - $15,000 Aug. 17, 2020
NVAX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
NVAX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
NVAX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by NVAX's directors and management

Corporate Lobbying

Government lobbying spending instances

  • $90,000 Oct 18, 2024 Issue: Health Issues
  • $90,000 Jul 17, 2024 Issue: Health Issues
  • $130,000 Apr 19, 2024 Issue: Health Issues
  • $120,000 Jan 19, 2024 Issue: Health Issues
  • $120,000 Oct 20, 2023 Issue: Health Issues
  • $120,000 Jul 20, 2023 Issue: Health Issues
  • $150,000 Jan 20, 2023 Issue: Health Issues
  • $110,000 Oct 21, 2022 Issue: Health Issues
  • $110,000 Jul 20, 2022 Issue: Health Issues
  • $160,000 Apr 19, 2022 Issue: Health Issues
  • $150,000 Jan 17, 2022 Issue: HEALTH ISSUES
  • $120,000 Oct 19, 2021 Issue: HEALTH ISSUES
  • $110,000 Jul 20, 2021 Issue: HEALTH ISSUES
  • $100,000 Apr 20, 2021 Issue: HEALTH ISSUES
  • $60,000 Jan 18, 2021 Issue: HEALTH ISSUES
  • $90,000 Oct 20, 2020 Issue: None
  • $50,000 Jul 22, 2020 Issue: None
  • $10,000 May 11, 2020 Issue: TAXATION/INTERNAL REVENUE CODE
  • $10,000 Jan 03, 2020 Issue: TAXATION/INTERNAL REVENUE CODE
  • $10,000 Oct 18, 2019 Issue: Taxation/Internal Revenue Code
  • $10,000 Jul 18, 2019 Issue: Health Issues Taxation/Internal Revenue Code
  • $10,000 Apr 17, 2019 Issue: Taxation/Internal Revenue Code Budget/Appropriations
  • $10,000 Jan 18, 2019 Issue: Health Issues Taxation/Internal Revenue Code
  • $10,000 Oct 10, 2018 Issue: Budget/Appropriations Health Issues Taxation/Internal Revenue Code
  • $20,000 Jul 20, 2018 Issue: Taxation/Internal Revenue Code Health Issues Budget/Appropriations
  • $20,000 Apr 18, 2018 Issue: Taxation/Internal Revenue Code Budget/Appropriations
  • $20,000 Jan 19, 2018 Issue: Taxation/Internal Revenue Code Health Issues
  • $30,000 Oct 20, 2017 Issue: Taxation/Internal Revenue Code
  • $30,000 Jul 20, 2017 Issue: Taxation/Internal Revenue Code Health Issues Budget/Appropriations
  • $10,000 Apr 20, 2017 Issue: Health Issues Budget/Appropriations
  • $20,000 Jan 20, 2017 Issue: Medicare/Medicaid Health Issues Budget/Appropriations
  • $50,000 Oct 18, 2016 Issue: Medicare/Medicaid Health Issues Budget/Appropriations
  • $10,000 Jul 25, 2016 Issue: Health Issues
  • $10,000 Jul 20, 2016 Issue: Health Issues
  • $30,000 Apr 20, 2016 Issue: Health Issues
  • $10,000 Jan 20, 2016 Issue: Health Issues
  • $10,000 Oct 20, 2015 Issue: Health Issues
  • $10,000 Jul 20, 2015 Issue: Health Issues
  • $10,000 Apr 20, 2015 Issue: Health Issues
  • $10,000 Jan 14, 2015 Issue: Health Issues
  • $15,000 Oct 17, 2014 Issue: Health Issues
  • $10,000 Sep 04, 2014 Issue: Health Issues
  • $20,000 Apr 18, 2014 Issue: Health Issues
  • $15,000 Jan 15, 2014 Issue: Health Issues
  • $10,000 Oct 14, 2013 Issue: Health Issues
  • $7,000 Jul 16, 2013 Issue: Health Issues
  • $30,000 Jul 19, 2011 Issue: Health Issues
  • $30,000 Apr 18, 2011 Issue: Health Issues
  • $30,000 Jan 19, 2011 Issue: Health Issues
  • $30,000 Oct 19, 2010 Issue: Health Issues
  • $30,000 Jul 17, 2010 Issue: Health Issues
  • $30,000 Apr 18, 2010 Issue: Health Issues
  • $30,000 Jan 20, 2010 Issue: Health Issues
  • $30,000 Oct 20, 2009 Issue: Health Issues
  • $30,000 Jul 20, 2009 Issue: Health Issues
  • $20,000 Apr 20, 2009 Issue: Financial Institutions/Investments/Securities
  • $20,000 Aug 09, 2006 Issue: Budget/Appropriations
  • $20,000 Feb 13, 2006 Issue: Budget/Appropriations
  • $20,000 Mar 26, 2002 Issue: Defense Budget/Appropriations Medical/Disease Research/Clinical Labs
Corporate Lobbying

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Methods and compositions for inducing immune responses against Mar. 26, 2024
  • Patent Title: Corona virus vaccine formulations Feb. 13, 2024
  • Patent Title: Multivalent influenza nanoparticle vaccines Feb. 13, 2024
  • Patent Title: Coronavirus vaccine formulations Jan. 03, 2023
  • Patent Title: Modified rsv f proteins and methods of their use Sep. 20, 2022
  • Patent Title: Vaccine compositions having improved stability and immunogenicity Jun. 21, 2022
  • Patent Title: Multivalent influenza nanoparticle vaccines Mar. 22, 2022
  • Patent Title: Coronavirus vaccine formulations Feb. 22, 2022
  • Patent Title: Vaccine compositions having improved stability and immunogenicity Feb. 22, 2022
  • Patent Title: Methods and compositions for inducing immune responses against clostridium difficile Sep. 21, 2021
  • Patent Title: Modified rsv f proteins and methods of their use Jul. 06, 2021
  • Patent Title: Coronavirus vaccine formulations Mar. 23, 2021
  • Patent Title: Composition comprising iscom particles and live micro-organisms Oct. 27, 2020
  • Patent Title: Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods Aug. 25, 2020
  • Patent Title: Influenza vaccine Aug. 11, 2020
  • Patent Title: Iscom preparation and use thereof Aug. 04, 2020
  • Patent Title: Functional influenza virus like particles (vlps) Aug. 04, 2020
  • Patent Title: Functional influenza virus-like particles (vlps) Feb. 04, 2020
  • Patent Title: Highly efficient influenza matrix (m1) proteins Jan. 28, 2020
  • Patent Title: Influenza vaccine Nov. 26, 2019
  • Patent Title: Vaccine compositions having improved stability and immunogenicity Oct. 01, 2019
  • Patent Title: Functional influenza virus like particles (vlps) Jan. 29, 2019
  • Patent Title: Rabies glycoprotein virus-like particles (vlps) Oct. 02, 2018
  • Patent Title: Modified rsv f proteins and methods of their use Jul. 17, 2018
  • Patent Title: Functional influenza virus-like particles (vlps) May. 01, 2018
  • Patent Title: Highly efficient influenza matrix (m1) proteins Apr. 24, 2018
  • Patent Title: Functional influenza virus-like particles (vlps) Apr. 10, 2018
  • Patent Title: Compositions comprising iscom particles and live micro-organisms Feb. 27, 2018
  • Patent Title: Modified rsv f proteins and methods of their use Aug. 15, 2017
  • Patent Title: Rabies glycoprotein virus-like particles (vlps) Aug. 08, 2017
  • Patent Title: Modified rsv f proteins and methods of their use Aug. 01, 2017
  • Patent Title: Functional influenza virus like particles (vlps) Jul. 04, 2017
  • Patent Title: Modified rsv f proteins and methods of their use Jun. 13, 2017
  • Patent Title: Functional influenza virus-like particles (vlps) Apr. 18, 2017
  • Patent Title: Functional influenza virus-like particles (vlps) Oct. 25, 2016
  • Patent Title: Highly efficient influenza matrix (m1) proteins Oct. 11, 2016
  • Patent Title: Vlps derived from cells that do not express a viral matrix or core protein Jul. 05, 2016
  • Patent Title: Composition comprising iscom particles and live micro-organisms Dec. 08, 2015
  • Patent Title: Functional influenza virus-like particles (vlps) Nov. 10, 2015
  • Patent Title: Functional influenza virus-like particles (vlps) Sep. 29, 2015
  • Patent Title: Functional influenza virus like particles (vlps) Jun. 09, 2015
  • Patent Title: Highly efficient influenza matrix (m1) proteins Mar. 31, 2015
  • Patent Title: Functional influenza virus-like particles (vlps) Feb. 10, 2015
  • Patent Title: Quil a fraction with low toxicity and use thereof Sep. 02, 2014
  • Patent Title: Modified rsv f proteins and methods of their use May. 06, 2014
  • Patent Title: Vlps derived from cells that do not express a viral matrix or core protein Apr. 15, 2014
  • Patent Title: Functional influenza virus-like particles (vlps) Nov. 26, 2013
  • Patent Title: Avian influenza chimeric vlps Oct. 08, 2013
  • Patent Title: Functional influenza virus like particles (vlps) Aug. 13, 2013
  • Patent Title: Functional influenza virus like particles (vlps) Dec. 20, 2011
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded from public contracts

WallStreetBets

Number of mentions of NVAX in WallStreetBets Daily Discussion

NVAX News

Recent insights relating to NVAX

CNBC Recommendations

Recent picks made for NVAX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in NVAX

NVAX Top Shareholders
Shareholder
Shares Held
NVAX Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

NVAX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view NVAX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top